Keyword: U.S. Patent & Trademark Office
Johnson & Johnson's prostate cancer drug Zytiga lost a key patent challenge that clears the way for cheap copycats later this year.
Allergan's anticompetitive behavior didn't begin with its tribal licensing deal to protect Restasis from rivals, a new lawsuit alleges.
Allergan CEO Brent Saunders said it was "tenacity," not "desperation," that led the company to enter into the tribal licensing deal.
Mylan and other generics makers urged a Texas judge to call Allergan's Restasis patent deal with the Saint Regis Mohawk Tribe a "sham."
Allergan inked a settlement that gets one more would-be generic challenger off its radar, for now.
Sanofi and Regeneron have gone the IPR route in their attempts to stop Amgen's patent infringement case over Dupixent. And so far, it hasn't worked.
Seeking to shield itself against a “double jeopardy” of IP challenges, Allergan has transferred key Restasis patents to the Saint Regis Mohawk Tribe.
Biogen has prevailed in a patent squabble with Forward Pharma over Tecfidera, but can the decision actually help the Big Biotech dodge generic rivals?
Acorda Therapeutics’ IP protection on Ampyra may have held up against an administrative patent challenge, but it didn't do the same in court.
Three strikes for the patents on Teva’s long-acting Copaxone formula, but the branded drug isn’t out of the exclusivity game yet.